Literature DB >> 25196220

Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed?

Larry Nichols1, Aaron Berg, Marian A Rollins-Raval, Jay S Raval.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially fatal disease. Early implementation of therapeutic plasma exchange (TPE) has decreased the mortality rate from >90% to <10%. However, fatalities still occur in these patients. The goal of this study was to characterize the causes of death and related postmortem findings in patients with TTP in the current era of emergent TPE to identify possible areas for improvement in the care of these patients. We analyzed clinical history, laboratory and histopathologic findings, and causes of death of patients with active TTP or TTP in clinical remission autopsied at our institution over 22 years. Of 18 patients, 15 had TTP judged to be a cause of death: it was an underlying cause of death in five cases, intermediate in three, and contributing in seven. The most common immediate causes of death were cardiac arrest and myocardial infarction. The most common TTP-related findings at autopsy were thrombi/emboli in heart (9), lung (11), brain (3), kidney (7), followed by hemorrhages in heart (7), lung (8), brain (2), kidney (7), and infarcts in heart (5), lung (4), brain (6) and kidney (3). Analysis of the cases with TTP as a cause of death suggests that the mechanism of death is commonly cardiac in origin. Proactive measures to monitor and protect the heart may be beneficial in these patients.
© 2014 The Authors. Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis.

Entities:  

Keywords:  Acute myocardial infarction; Acute myocardial ischemia; Autopsy; Causes of death; Thrombocytopenia; Thrombotic thrombocytopenic purpura.

Mesh:

Year:  2014        PMID: 25196220     DOI: 10.1111/1744-9987.12191

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  6 in total

1.  Obstructive coronary artery disease in patient with acute thrombotic thrombocytopenic purpura.

Authors:  Szymon L Wiernek; Xuming Dai
Journal:  BMJ Case Rep       Date:  2017-10-15

2.  Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012.

Authors:  Ruchika Goel; Karen E King; Clifford M Takemoto; Paul M Ness; Aaron A R Tobian
Journal:  Transfusion       Date:  2016-04-15       Impact factor: 3.157

Review 3.  Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Muhammad Haisum Maqsood; Kinza Rubab; Muhammad Zaigham Maqsood
Journal:  Cureus       Date:  2019-07-29

4.  Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study.

Authors:  Wolfgang Miesbach; Jan Menne; Martin Bommer; Ulf Schönermarck; Thorsten Feldkamp; Martin Nitschke; Timm H Westhoff; Felix S Seibert; Rainer Woitas; Rui Sousa; Michael Wolf; Stefan Walzer; Björn Schwander
Journal:  Orphanet J Rare Dis       Date:  2019-11-15       Impact factor: 4.123

5.  Unmet needs in the management of immune-mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK-A modified-Delphi study.

Authors:  Marie Scully; Tina Dutt; Will Lester; Emily Farrington; Stevie Lockwood; Richard Perry; Steve Holmes
Journal:  EJHaem       Date:  2022-04-28

6.  Myocardial Infarction as an Early Presentation in Thrombotic Thrombocytopenic Purpura: A Rare Case Series.

Authors:  Sumit Dahal; Dipesh K C Ghimire; Saroj Sapkota; Suyash Dahal; Paritosh Kafle; Manjul Bhandari
Journal:  J Investig Med High Impact Case Rep       Date:  2018-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.